Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 172

1.

Lenalidomide Combination Therapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma: The Italian Real-Life Experience.

Marangon M, Stefoni V, Castellino A, Visco C, Tani M, Cox MC, Marasca R, Tecchio C, Devizzi L, Monaco F, Romano A, Rusconi C, Rigacci L, Castellino C, Gaudio F, Argnani L, Zinzani PL.

Clin Lymphoma Myeloma Leuk. 2019 Jul;19(7):e321-e323. doi: 10.1016/j.clml.2019.03.020. Epub 2019 Mar 29. No abstract available.

PMID:
31080169
2.

Lenalidomide in Pretreated Patients with Diffuse Large B-Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice.

Broccoli A, Casadei B, Chiappella A, Visco C, Tani M, Cascavilla N, Conconi A, Balzarotti M, Cox MC, Marino D, Goldaniga MC, Marasca R, Tecchio C, Patti C, Musuraca G, Devizzi L, Monaco F, Romano A, Fama A, Zancanella M, Paolini R, Rigacci L, Castellino C, Gaudio F, Argnani L, Zinzani PL.

Oncologist. 2019 Apr 2. pii: theoncologist.2018-0603. doi: 10.1634/theoncologist.2018-0603. [Epub ahead of print]

PMID:
30940746
3.

Characterization and dynamics of specific T cells against nucleophosmin-1 (NPM1)-mutated peptides in patients with NPM1-mutated acute myeloid leukemia.

Forghieri F, Riva G, Lagreca I, Barozzi P, Vallerini D, Morselli M, Paolini A, Bresciani P, Colaci E, Maccaferri M, Gilioli A, Nasillo V, Messerotti A, Pioli V, Arletti L, Giusti D, Bettelli F, Celli M, Donatelli F, Corradini G, Basso S, Gurrado A, Cellini M, Trenti T, Marasca R, Narni F, Martelli MP, Falini B, Potenza L, Luppi M, Comoli P.

Oncotarget. 2019 Jan 25;10(8):869-882. doi: 10.18632/oncotarget.26617. eCollection 2019 Jan 25.

4.

Overexpression of CD49d in trisomy 12 chronic lymphocytic leukemia patients is mediated by IRF4 through induction of IKAROS.

Fiorcari S, Benatti S, Zucchetto A, Zucchini P, Gattei V, Luppi M, Marasca R, Maffei R.

Leukemia. 2019 May;33(5):1278-1302. doi: 10.1038/s41375-018-0296-5. Epub 2019 Jan 18. No abstract available.

PMID:
30659236
5.

Minimal/Measurable Residual Disease Monitoring in NPM1-Mutated Acute Myeloid Leukemia: A Clinical Viewpoint and Perspectives.

Forghieri F, Comoli P, Marasca R, Potenza L, Luppi M.

Int J Mol Sci. 2018 Nov 6;19(11). pii: E3492. doi: 10.3390/ijms19113492. Review.

6.

Peripheral lymphadenopathy: role of excisional biopsy in differential diagnosis based on a five-year experience.

Campanelli M, Cabry F, Marasca R, Gelmini R.

Minerva Chir. 2019 Jun;74(3):218-223. doi: 10.23736/S0026-4733.18.07752-0. Epub 2018 Oct 9.

PMID:
30306770
7.

Idelalisib impairs T-cell-mediated immunity in chronic lymphocytic leukemia.

Martinelli S, Maffei R, Fiorcari S, Quadrelli C, Zucchini P, Benatti S, Potenza L, Luppi M, Marasca R.

Haematologica. 2018 Dec;103(12):e598-e601. doi: 10.3324/haematol.2017.187070. Epub 2018 Jul 5. No abstract available.

8.

Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphoma.

Broccoli A, Casadei B, Morigi A, Sottotetti F, Gotti M, Spina M, Volpetti S, Ferrero S, Spina F, Pisani F, Merli M, Visco C, Paolini R, Zilioli VR, Baldini L, Di Renzo N, Tosi P, Cascavilla N, Molica S, Ilariucci F, Rigolin GM, D'Alò F, Vanazzi A, Santambrogio E, Marasca R, Mastrullo L, Castellino C, Desabbata G, Scortechini I, Trentin L, Morello L, Argnani L, Zinzani PL.

Oncotarget. 2018 May 4;9(34):23443-23450. doi: 10.18632/oncotarget.25215. eCollection 2018 May 4.

9.

Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study.

Cuneo A, Follows G, Rigolin GM, Piciocchi A, Tedeschi A, Trentin L, Perez AM, Coscia M, Laurenti L, Musuraca G, Farina L, Delgado AR, Orlandi EM, Galieni P, Mauro FR, Visco C, Amendola A, Billio A, Marasca R, Chiarenza A, Meneghini V, Ilariucci F, Marchetti M, Molica S, Re F, Gaidano G, Gonzalez M, Forconi F, Ciolli S, Cortelezzi A, Montillo M, Smolej L, Schuh A, Eyre TA, Kennedy B, Bowles KM, Vignetti M, de la Serna J, Moreno C, Foà R, Ghia P; GIMEMA, European Research Initiative on CLL (ERIC) and UK CLL forum.

Haematologica. 2018 Jul;103(7):1209-1217. doi: 10.3324/haematol.2018.189837. Epub 2018 Apr 19.

10.

Lenalidomide in Pretreated Mantle Cell Lymphoma Patients: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice (the Lenamant Study).

Stefoni V, Pellegrini C, Broccoli A, Baldini L, Tani M, Cencini E, Figuera A, Ansuinelli M, Bernocco E, Cantonetti M, Cox MC, Ballerini F, Rusconi C, Visco C, Arcaini L, Fama A, Marasca R, Volpetti S, Castellino A, Califano C, Cavaliere M, Gini G, Liberati AM, Musuraca G, Lucania A, Ricciuti G, Argnani L, Zinzani PL.

Oncologist. 2018 Sep;23(9):1033-1038. doi: 10.1634/theoncologist.2017-0597. Epub 2018 Apr 19.

PMID:
29674440
11.

Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding.

Boriani G, Corradini P, Cuneo A, Falanga A, Foà R, Gaidano G, Ghia PP, Martelli M, Marasca R, Massaia M, Mauro FR, Minotti G, Molica S, Montillo M, Pinto A, Tedeschi A, Vitolo U, Zinzani PL.

Hematol Oncol. 2018 Oct;36(4):624-632. doi: 10.1002/hon.2503. Epub 2018 Mar 7. Review.

PMID:
29512173
12.

Macitentan, a double antagonist of endothelin receptors, efficiently impairs migration and microenvironmental survival signals in chronic lymphocytic leukemia.

Maffei R, Fiorcari S, Vaisitti T, Martinelli S, Benatti S, Debbia G, Rossi D, Zucchini P, Potenza L, Luppi M, Gaidano G, Deaglio S, Marasca R.

Oncotarget. 2017 Sep 27;8(52):90013-90027. doi: 10.18632/oncotarget.21341. eCollection 2017 Oct 27.

13.

Increased SHISA3 expression characterizes chronic lymphocytic leukemia patients sensitive to lenalidomide.

Maffei R, Fiorcari S, Martinelli S, Benatti S, Bulgarelli J, Rizzotto L, Debbia G, Santachiara R, Rigolin GM, Forconi F, Rossi D, Laurenti L, Palumbo GA, Vallisa D, Cuneo A, Gaidano G, Luppi M, Marasca R.

Leuk Lymphoma. 2018 Feb;59(2):423-433. doi: 10.1080/10428194.2017.1339872. Epub 2017 Jun 22.

PMID:
28639485
14.

Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: correlation with biologically-based risk stratification.

Laurenti L, Innocenti I, Autore F, Ciolli S, Mauro FR, Mannina D, Del Poeta G, D'Arena G, Massaia M, Coscia M, Molica S, Pozzato G, Efremov DG, Vannata B, Marasca R, Galieni P, Cuneo A, Orlando S, Piciocchi A, Boncompagni R, Vincelli D, Liberati AM, Russo F, Foá R.

Haematologica. 2017 Sep;102(9):e352-e355. doi: 10.3324/haematol.2016.156901. Epub 2017 Jun 8. No abstract available.

15.

Effectiveness of originator (Neupogen) and biosimilar (Zarzio) filgrastim in autologous peripheral blood stem cell mobilization in adults with acute myeloid leukemia: a single-center retrospective study.

Nasillo V, Paolini A, Riva G, Morselli M, Potenza L, Coluccio V, Maccaferri M, Colaci E, Fantuzzi V, Messerotti A, Arletti L, Pioli V, Lugli E, Gilioli A, Quadrelli C, Zucchini P, Vallerini D, Lagreca I, Barozzi P, Cuoghi A, Bresciani P, Marasca R, Mariano MT, Ceccherelli G, Comoli P, Campioli D, Trenti T, Narni F, Luppi M, Forghieri F.

Leuk Lymphoma. 2018 Jan;59(1):225-228. doi: 10.1080/10428194.2017.1321748. Epub 2017 Jun 7. No abstract available.

PMID:
28587560
16.

Angiopoietin-2 acts as a survival factor for chronic lymphocytic leukemia B cells throughout Tie-2 receptor engagement.

Maffei R, Fiorcari S, Martinelli S, Guarnotta C, Benatti S, Belmonte B, Potenza L, Luppi M, Marasca R.

Hematol Oncol. 2018 Feb;36(1):372-375. doi: 10.1002/hon.2448. Epub 2017 Jun 4. No abstract available.

PMID:
28580615
17.

The expression of endothelin-1 in chronic lymphocytic leukemia is controlled by epigenetic mechanisms and extracellular stimuli.

Martinelli S, Maffei R, Fiorcari S, Quadrelli C, Zucchini P, Benatti S, Potenza L, Luppi M, Marasca R.

Leuk Res. 2017 Mar;54:17-24. doi: 10.1016/j.leukres.2016.12.006. Epub 2016 Dec 30.

PMID:
28092772
18.

Detection of Fusarium-specific T cells in hematologic patients with invasive fusariosis.

Vallerini D, Forghieri F, Lagreca I, Riva G, Barozzi P, Quadrelli C, Morselli M, Bresciani P, Cuoghi A, Coluccio V, Maccaferri M, Paolini A, Colaci E, Marasca R, Narni F, Cellini M, Beauvais A, Latgè JP, Romani L, Iughetti L, Comoli P, Campioli D, Trenti T, Luppi M, Potenza L.

J Infect. 2017 Mar;74(3):314-318. doi: 10.1016/j.jinf.2016.12.008. Epub 2016 Dec 23. No abstract available.

PMID:
28017824
19.

All-trans retinoic acid (ATRA) in non-promyelocytic acute myeloid leukemia (AML): results of combination of ATRA with low-dose Ara-C in three elderly patients with NPM1-mutated AML unfit for intensive chemotherapy and review of the literature.

Forghieri F, Bigliardi S, Quadrelli C, Morselli M, Potenza L, Paolini A, Colaci E, Barozzi P, Zucchini P, Riva G, Vallerini D, Lagreca I, Marasca R, Narni F, Venditti A, Martelli MP, Falini B, Lo Coco F, Amadori S, Luppi M.

Clin Case Rep. 2016 Oct 24;4(12):1138-1146. eCollection 2016 Dec.

20.

BCR-ABL-specific T-cell therapy in Ph+ ALL patients on tyrosine-kinase inhibitors.

Comoli P, Basso S, Riva G, Barozzi P, Guido I, Gurrado A, Quartuccio G, Rubert L, Lagreca I, Vallerini D, Forghieri F, Morselli M, Bresciani P, Cuoghi A, Paolini A, Colaci E, Marasca R, Cuneo A, Iughetti L, Trenti T, Narni F, Foà R, Zecca M, Luppi M, Potenza L.

Blood. 2017 Feb 2;129(5):582-586. doi: 10.1182/blood-2016-07-731091. Epub 2016 Dec 7.

21.

A population-based study of chronic myeloid leukemia patients treated with imatinib in first line.

Castagnetti F, Di Raimondo F, De Vivo A, Spitaleri A, Gugliotta G, Fabbiano F, Capodanno I, Mannina D, Salvucci M, Antolino A, Marasca R, Musso M, Crugnola M, Impera S, Trabacchi E, Musolino C, Cavazzini F, Mineo G, Tosi P, Tomaselli C, Rizzo M, Siragusa S, Fogli M, Ragionieri R, Zironi A, Soverini S, Martinelli G, Cavo M, Vigneri P, Stagno F, Rosti G, Baccarani M.

Am J Hematol. 2017 Jan;92(1):82-87. doi: 10.1002/ajh.24591. Epub 2016 Nov 18.

22.

Ibrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemia.

Fiorcari S, Maffei R, Audrito V, Martinelli S, Ten Hacken E, Zucchini P, Grisendi G, Potenza L, Luppi M, Burger JA, Deaglio S, Marasca R.

Oncotarget. 2016 Oct 4;7(40):65968-65981. doi: 10.18632/oncotarget.11782.

23.

Circulating functional T cells specific to human herpes virus 6 (HHV6) antigens in individuals with chromosomally integrated HHV6.

Barozzi P, Riva G, Vallerini D, Quadrelli C, Lagreca I, Eccheli R, Forghieri F, Coluccio V, Maccaferri M, Paolini A, Colaci E, Morselli M, Marasca R, Narni F, Comoli P, Campioli D, Trenti T, Potenza L, Luppi M.

Clin Microbiol Infect. 2016 Oct;22(10):893-895. doi: 10.1016/j.cmi.2016.07.006. Epub 2016 Jul 9. No abstract available.

24.

The importance of cytogenetic and molecular analyses in eosinophilia-associated myeloproliferative neoplasms: an unusual case with normal karyotype and TNIP1- PDGFRB rearrangement and overview of PDGFRB partner genes.

Maccaferri M, Pierini V, Di Giacomo D, Zucchini P, Forghieri F, Bonacorsi G, Paolini A, Quadrelli C, Giacobbi F, Fontana F, Cappelli G, Potenza L, Marasca R, Luppi M, Mecucci C.

Leuk Lymphoma. 2017 Feb;58(2):489-493. Epub 2016 Jun 24. Review. No abstract available.

PMID:
27337990
25.

The genetics of nodal marginal zone lymphoma.

Spina V, Khiabanian H, Messina M, Monti S, Cascione L, Bruscaggin A, Spaccarotella E, Holmes AB, Arcaini L, Lucioni M, Tabbò F, Zairis S, Diop F, Cerri M, Chiaretti S, Marasca R, Ponzoni M, Deaglio S, Ramponi A, Tiacci E, Pasqualucci L, Paulli M, Falini B, Inghirami G, Bertoni F, Foà R, Rabadan R, Gaidano G, Rossi D.

Blood. 2016 Sep 8;128(10):1362-73. doi: 10.1182/blood-2016-02-696757. Epub 2016 Jun 22.

26.

Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM.

Jakubowiak A, Offidani M, Pégourie B, De La Rubia J, Garderet L, Laribi K, Bosi A, Marasca R, Laubach J, Mohrbacher A, Carella AM, Singhal AK, Tsao LC, Lynch M, Bleickardt E, Jou YM, Robbins M, Palumbo A.

Blood. 2016 Jun 9;127(23):2833-40. doi: 10.1182/blood-2016-01-694604. Epub 2016 Apr 18.

27.

Mucorales-Specific T Cells in Patients with Hematologic Malignancies.

Potenza L, Vallerini D, Barozzi P, Riva G, Gilioli A, Forghieri F, Candoni A, Cesaro S, Quadrelli C, Maertens J, Rossi G, Morselli M, Codeluppi M, Mussini C, Colaci E, Messerotti A, Paolini A, Maccaferri M, Fantuzzi V, Del Giovane C, Stefani A, Morandi U, Maffei R, Marasca R, Narni F, Fanin R, Comoli P, Romani L, Beauvais A, Viale PL, Latgè JP, Lewis RE, Luppi M.

PLoS One. 2016 Feb 12;11(2):e0149108. doi: 10.1371/journal.pone.0149108. eCollection 2016.

28.

The bone marrow represents an enrichment site of specific T lymphocytes against filamentous fungi.

Vallerini D, Riva G, Barozzi P, Forghieri F, Lagreca I, Quadrelli C, Morselli M, Bresciani P, Cuoghi A, Coluccio V, Maccaferri M, Paolini A, Colaci E, Marasca R, Narni F, Latgè JP, Romani L, Comoli P, Campioli D, Trenti T, Luppi M, Potenza L.

Med Mycol. 2016 Mar;54(3):327-32. doi: 10.1093/mmy/myv107. Epub 2015 Dec 24.

PMID:
26705835
29.

Chronic and recurrent benign lymphadenopathy without constitutional symptoms associated with human herpesvirus-6B reactivation.

Forghieri F, Luppi M, Barozzi P, Riva G, Morselli M, Bigliardi S, Quadrelli C, Vallerini D, Maccaferri M, Coluccio V, Paolini A, Colaci E, Bonacorsi G, Maiorana A, Tagliazucchi S, Rumpianesi F, Mattioli F, Presutti L, Gelmini R, Cermelli C, Rossi G, Comoli P, Marasca R, Narni F, Potenza L.

Br J Haematol. 2016 Feb;172(4):561-72. doi: 10.1111/bjh.13871. Epub 2015 Dec 18.

PMID:
26684692
30.

Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter study.

Arcari A, Chiappella A, Spina M, Zanlari L, Bernuzzi P, Valenti V, Tani M, Marasca R, Cabras MG, Zambello R, Santagostino A, Ilariucci F, Carli G, Musto P, Savini P, Marino D, Ghio F, Gentile M, Cox MC, Vallisa D.

Leuk Lymphoma. 2016 Aug;57(8):1823-30. doi: 10.3109/10428194.2015.1106536. Epub 2015 Dec 15.

PMID:
26666433
31.

Lenalidomide in chronic lymphocytic leukemia: the present and future in the era of tyrosine kinase inhibitors.

Maffei R, Colaci E, Fiorcari S, Martinelli S, Potenza L, Luppi M, Marasca R.

Crit Rev Oncol Hematol. 2016 Jan;97:291-302. doi: 10.1016/j.critrevonc.2015.09.003. Epub 2015 Sep 30. Review.

PMID:
26454471
32.

Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia.

Rossi D, Terzi-di-Bergamo L, De Paoli L, Cerri M, Ghilardi G, Chiarenza A, Bulian P, Visco C, Mauro FR, Morabito F, Cortelezzi A, Zaja F, Forconi F, Laurenti L, Del Giudice I, Gentile M, Vincelli I, Motta M, Coscia M, Rigolin GM, Tedeschi A, Neri A, Marasca R, Perbellini O, Moreno C, Del Poeta G, Massaia M, Zinzani PL, Montillo M, Cuneo A, Gattei V, Foà R, Gaidano G.

Blood. 2015 Oct 15;126(16):1921-4. doi: 10.1182/blood-2015-05-647925. Epub 2015 Aug 14.

33.

Antineoplastic effects of liposomal short interfering RNA treatment targeting BLIMP1/PRDM1 in primary effusion lymphoma.

Riva G, Lagreca I, Mattiolo A, Belletti D, Lignitto L, Barozzi P, Ruozi B, Vallerini D, Quadrelli C, Corradini G, Forghieri F, Marasca R, Narni F, Tosi G, Forni F, Vandelli MA, Amadori A, Chieco-Bianchi L, Potenza L, Calabrò ML, Luppi M.

Haematologica. 2015 Nov;100(11):e467-70. doi: 10.3324/haematol.2015.126854. Epub 2015 Jul 23. No abstract available.

34.

Epidemiology and clinical outcome of lower respiratory tract infections by respiratory syncytial virus or parainfluenza virus type 3 in adults receiving treatment for either acute leukemia or severe aplastic anemia: a retrospective single center study.

Bigliardi S, Morselli M, Potenza L, Riva G, Coluccio V, Maccaferri M, Paolini A, Colaci E, Fantuzzi V, Soci F, Nasillo V, Messerotti A, Arletti L, Pioli V, Lugli E, Gilioli A, Quadrelli C, Vallerini D, Barozzi P, Lagreca I, Marasca R, Narni F, Franceschini E, Codeluppi M, Mussini C, Luppi M, Forghieri F.

Ann Hematol. 2015 Nov;94(11):1931-4. doi: 10.1007/s00277-015-2455-3. Epub 2015 Jul 25. No abstract available.

PMID:
26204825
35.

First report of FIP1L1-PDGFRα-positive eosinophilic granulomatosis with polyangiitis.

Emmi G, Silvestri E, Marconi R, Carrai V, Fanelli T, Zucchini P, Marasca R, Vannucchi AM, Emmi L, Prisco D, Vaglio A.

Rheumatology (Oxford). 2015 Sep;54(9):1751-3. doi: 10.1093/rheumatology/kev242. Epub 2015 Jun 23. No abstract available.

PMID:
26106208
36.

Targeting neoplastic B cells and harnessing microenvironment: the "double face" of ibrutinib and idelalisib.

Maffei R, Fiorcari S, Martinelli S, Potenza L, Luppi M, Marasca R.

J Hematol Oncol. 2015 May 29;8:60. doi: 10.1186/s13045-015-0157-x. Review.

37.

NPM1 mutations may reveal acute myeloid leukemia in cases otherwise morphologically diagnosed as myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms.

Forghieri F, Paolini A, Morselli M, Bigliardi S, Bonacorsi G, Leonardi G, Coluccio V, Maccaferri M, Fantuzzi V, Faglioni L, Colaci E, Soci F, Nasillo V, Messerotti A, Arletti L, Pioli V, Zucchini P, Quadrelli C, Corradini G, Giacobbi F, Vallerini D, Riva G, Barozzi P, Lagreca I, Marasca R, Narni F, Mecucci C, Ottaviani E, Martinelli G, Falini B, Luppi M, Potenza L.

Leuk Lymphoma. 2015;56(11):3222-6. doi: 10.3109/10428194.2015.1026900. Epub 2015 May 12. Review. No abstract available.

PMID:
25813079
38.

DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features.

Arribas AJ, Rinaldi A, Mensah AA, Kwee I, Cascione L, Robles EF, Martinez-Climent JA, Oscier D, Arcaini L, Baldini L, Marasca R, Thieblemont C, Briere J, Forconi F, Zamò A, Bonifacio M, Mollejo M, Facchetti F, Dirnhofer S, Ponzoni M, Bhagat G, Piris MA, Gaidano G, Zucca E, Rossi D, Bertoni F.

Blood. 2015 Mar 19;125(12):1922-31. doi: 10.1182/blood-2014-08-596247. Epub 2015 Jan 22.

39.

Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia.

Moreno C, Montillo M, Panayiotidis P, Dimou M, Bloor A, Dupuis J, Schuh A, Norin S, Geisler C, Hillmen P, Doubek M, Trněný M, Obrtlikova P, Laurenti L, Stilgenbauer S, Smolej L, Ghia P, Cymbalista F, Jaeger U, Stamatopoulos K, Stavroyianni N, Carrington P, Zouabi H, Leblond V, Gomez-Garcia JC, Rubio M, Marasca R, Musuraca G, Rigacci L, Farina L, Paolini R, Pospisilova S, Kimby E, Bradley C, Montserrat E.

Haematologica. 2015 Apr;100(4):511-6. doi: 10.3324/haematol.2014.118158. Epub 2015 Jan 16.

40.

Tumor evolutionary directed graphs and the history of chronic lymphocytic leukemia.

Wang J, Khiabanian H, Rossi D, Fabbri G, Gattei V, Forconi F, Laurenti L, Marasca R, Del Poeta G, Foà R, Pasqualucci L, Gaidano G, Rabadan R.

Elife. 2014 Dec 11;3. doi: 10.7554/eLife.02869.

41.

Lenalidomide interferes with tumor-promoting properties of nurse-like cells in chronic lymphocytic leukemia.

Fiorcari S, Martinelli S, Bulgarelli J, Audrito V, Zucchini P, Colaci E, Potenza L, Narni F, Luppi M, Deaglio S, Marasca R, Maffei R.

Haematologica. 2015 Feb;100(2):253-62. doi: 10.3324/haematol.2014.113217. Epub 2014 Nov 14.

42.

The Krüppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma.

Piva R, Deaglio S, Famà R, Buonincontri R, Scarfò I, Bruscaggin A, Mereu E, Serra S, Spina V, Brusa D, Garaffo G, Monti S, Dal Bo M, Marasca R, Arcaini L, Neri A, Gattei V, Paulli M, Tiacci E, Bertoni F, Pileri SA, Foà R, Inghirami G, Gaidano G, Rossi D.

Leukemia. 2015 Feb;29(2):503-7. doi: 10.1038/leu.2014.294. Epub 2014 Oct 6. No abstract available.

PMID:
25283840
43.

Severe anemia in a patient with multiple sclerosis treated with natalizumab.

Simone AM, Ferraro D, Vitetta F, Marasca R, Bonacorsi G, Pinelli G, Federzoni L, Nichelli PF, Sola P.

Neurology. 2014 Jul 22;83(4):374-5. doi: 10.1212/WNL.0000000000000614. Epub 2014 Jun 18. No abstract available.

PMID:
24944259
44.

Endothelin-1 promotes survival and chemoresistance in chronic lymphocytic leukemia B cells through ETA receptor.

Maffei R, Bulgarelli J, Fiorcari S, Martinelli S, Castelli I, Valenti V, Rossi D, Bonacorsi G, Zucchini P, Potenza L, Vallisa D, Gattei V, Del Poeta G, Forconi F, Gaidano G, Narni F, Luppi M, Marasca R.

PLoS One. 2014 Jun 5;9(6):e98818. doi: 10.1371/journal.pone.0098818. eCollection 2014.

45.

An unusual case of B-ALL occurring in a patient with acute promyelocytic leukemia in remission after two hematopoietic SCTs: whose are the leukemic cells?

Bigliardi S, Morselli M, Potenza L, Bresciani P, Cuoghi A, Coluccio V, Riva G, Paolini A, Fantuzzi V, Faglioni L, Nasillo V, Messerotti A, Marasca R, Narni F, Luppi M, Forghieri F.

Bone Marrow Transplant. 2014 Sep;49(9):1237-8. doi: 10.1038/bmt.2014.119. Epub 2014 Jun 2. No abstract available.

PMID:
24887386
46.

NOX-A12: mobilizing CLL away from home.

Marasca R, Maffei R.

Blood. 2014 Feb 13;123(7):952-3. doi: 10.1182/blood-2013-12-542480. No abstract available.

47.

Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.

Palumbo A, Bringhen S, Larocca A, Rossi D, Di Raimondo F, Magarotto V, Patriarca F, Levi A, Benevolo G, Vincelli ID, Grasso M, Franceschini L, Gottardi D, Zambello R, Montefusco V, Falcone AP, Omedé P, Marasca R, Morabito F, Mina R, Guglielmelli T, Nozzoli C, Passera R, Gaidano G, Offidani M, Ria R, Petrucci MT, Musto P, Boccadoro M, Cavo M.

J Clin Oncol. 2014 Mar 1;32(7):634-40. doi: 10.1200/JCO.2013.52.0023. Epub 2014 Jan 21.

PMID:
24449241
48.

The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cells.

Fiorcari S, Brown WS, McIntyre BW, Estrov Z, Maffei R, O'Brien S, Sivina M, Hoellenriegel J, Wierda WG, Keating MJ, Ding W, Kay NE, Lannutti BJ, Marasca R, Burger JA.

PLoS One. 2013 Dec 23;8(12):e83830. doi: 10.1371/journal.pone.0083830. eCollection 2013.

49.

Ruxolitinib for pulmonary extramedullary hematopoiesis in myelofibrosis.

Maccaferri M, Leonardi G, Marasca R, Colaci E, Paolini A, Soci F, Forghieri F, Potenza L, Narni F, Luppi M.

Leuk Lymphoma. 2014 Sep;55(9):2207-8. doi: 10.3109/10428194.2013.873538. Epub 2014 Jan 28. No abstract available.

PMID:
24354678
50.

Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile.

Mauro FR, Molica S, Laurenti L, Cortelezzi A, Carella AM, Zaja F, Chiarenza A, Angrilli F, Nobile F, Marasca R, Musolino C, Brugiatelli M, Piciocchi A, Vignetti M, Fazi P, Gentile G, De Propris MS, Della Starza I, Marinelli M, Chiaretti S, Del Giudice I, Nanni M, Albano F, Cuneo A, Guarini A, Foà R; Gruppo Italiano Malattie EMatologiche dell’Adulto Working Party for Chronic Lymphoproliferative Disorders.

Leuk Res. 2014 Feb;38(2):198-203. doi: 10.1016/j.leukres.2013.11.009. Epub 2013 Nov 19.

Supplemental Content

Loading ...
Support Center